### DAY 1: Tuesday, 26 June 2018

<table>
<thead>
<tr>
<th>Duration</th>
<th>Proposed topic (PDVAC priority pathogens*)</th>
<th>Proposed speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800 – 0830</td>
<td>Meeting Registration</td>
<td></td>
</tr>
<tr>
<td>0830 – 0845</td>
<td>Opening of Meeting</td>
<td>Martin Friede (WHO) David Kaslow (PATH)</td>
</tr>
<tr>
<td>0845 – 0905</td>
<td>A year in review for PDVAC</td>
<td>Birgitte Giersing (WHO)</td>
</tr>
<tr>
<td>0905 – 0925</td>
<td>Update from WHO SAGE⁴ committee</td>
<td>Alejandro Cravioto (SAGE)</td>
</tr>
<tr>
<td>0925 - 0955</td>
<td>Update from other IVB committees: IPAC¹ and IVIRAC²</td>
<td>Raymond Hutubessy (WHO) Tania Cernuschi (WHO)</td>
</tr>
<tr>
<td>0955 – 1010</td>
<td>GAVI’s Vaccine Investment Strategy</td>
<td>Deepali Patel (GAVI)</td>
</tr>
<tr>
<td>1010 – 1030</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>1030 – 1045</td>
<td>WHO R&amp;D Blueprint</td>
<td>Vasee Moorthy (WHO)</td>
</tr>
<tr>
<td>1045 – 1115</td>
<td>Bridging Vaccine Development with Licensure and Use in Low and Middle Income Countries</td>
<td>Vasee Moorthy (WHO)</td>
</tr>
<tr>
<td>1115 - 1125</td>
<td>Money &amp; Microbes: Strengthening Clinical Research Capacity to prevent epidemics</td>
<td>Claudio Lanata (IIN)</td>
</tr>
<tr>
<td>1125 – 1210</td>
<td>The role of Controlled Human Infection Models in licensure of vaccines</td>
<td>Christopher Chiu (Imperial College, UK) Calman MacLennan (BMGF)</td>
</tr>
</tbody>
</table>

#### GVAP vaccines

<table>
<thead>
<tr>
<th>Duration</th>
<th>Proposed topic (Seasonal, universal and pandemic)</th>
<th>Proposed speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1210 – 1255</td>
<td>Influenza</td>
<td>Barney Graham (VRC, NIAID) Martin Friede (WHO)</td>
</tr>
<tr>
<td><strong>1255 - 1345</strong></td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>1345 - 1430</td>
<td>Tuberculosis (New generation vaccines)*</td>
<td>Mark Hatherill (SATVI)</td>
</tr>
<tr>
<td>1430 – 1500</td>
<td>Malaria*</td>
<td>Chris Ockenhouse (PATH)</td>
</tr>
<tr>
<td>1500 - 1545</td>
<td>Human Immunodeficiency Virus*</td>
<td>Kundai Chinyenze (IAVI)</td>
</tr>
<tr>
<td>1545 – 1615</td>
<td>Coffee</td>
<td></td>
</tr>
</tbody>
</table>

#### Sexually transmitted infections

<table>
<thead>
<tr>
<th>Duration</th>
<th>Proposed topic</th>
<th>Proposed speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1615 – 1730</td>
<td>Herpes Simplex Virus* and Gonorrhoea</td>
<td>Carolyn Deal (NIAID) Sami Gottlieb (WHO)</td>
</tr>
</tbody>
</table>

#### Vaccines to be administered by Maternal Immunization

<table>
<thead>
<tr>
<th>Duration</th>
<th>Proposed topic</th>
<th>Proposed speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1730 - 1800</td>
<td>WHO Maternal Immunization platform update</td>
<td>Ike Ogbuanu (WHO)</td>
</tr>
<tr>
<td>1800 – 1930</td>
<td>Cocktail</td>
<td></td>
</tr>
</tbody>
</table>
### DAY 2: Wednesday 27 June 2018

<table>
<thead>
<tr>
<th>Duration</th>
<th>Proposed topic</th>
<th>Proposed speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830 – 0915</td>
<td>Respiratory Syncytial Virus*</td>
<td>Danny Feikin (Independent)</td>
</tr>
<tr>
<td>0915 - 1000</td>
<td>Group B Streptococcus*</td>
<td>Kirsty LeDoare (Imperial College, London)</td>
</tr>
<tr>
<td>1000 - 1030</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>1030 - 1100</td>
<td>Value of Vaccines in the Avoidance of AMR</td>
<td>Padmini Srikantiah (BMGF)</td>
</tr>
<tr>
<td>1100 - 1145</td>
<td>Group A Streptococcus*</td>
<td>Andrew Steer (Murdoch Children’s Research Institute)/Jerome Kim (IVI)</td>
</tr>
<tr>
<td>1145 – 1215</td>
<td>BMGF perspectives on diarrhoea etiology estimates from recent studies using molecular methods</td>
<td>Anita Zaidi (BMGF)</td>
</tr>
<tr>
<td>1215 – 1300</td>
<td>Next generation rotavirus vaccines</td>
<td>Duncan Steele (BMGF)</td>
</tr>
<tr>
<td>1300 - 1400</td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>1400 – 1445</td>
<td>Enterotoxigenic E. coli (ETEC)*</td>
<td>Lou Bourgeois (PATH)</td>
</tr>
<tr>
<td>1445 – 1515</td>
<td>Shigella*</td>
<td>Mark Riddle (USUHS)</td>
</tr>
<tr>
<td>1515 – 1545</td>
<td>Non-typhoidal salmonella</td>
<td>Cal MacLennan (BMGF/Univ of Oxford)</td>
</tr>
<tr>
<td>1545 – 1605</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>1605 – 1620</td>
<td>Nucleic acid-based vaccines</td>
<td>Rebecca Sheets (Independent)</td>
</tr>
<tr>
<td>1620 - 1635</td>
<td>Chikungunya</td>
<td>Gagandeep Kang (THSTI)</td>
</tr>
<tr>
<td>1635 – 1655</td>
<td>Dengue</td>
<td>Annelies Wilder-Smith (WHO/independent)</td>
</tr>
<tr>
<td>1655 – 1725</td>
<td>Total Systems Effectiveness &amp; Vaccine Innovation Prioritization Strategy (VIPS)</td>
<td>Birgitte Giersing (WHO) &amp; Marion Menozzi-Arnaud (GAVI)</td>
</tr>
<tr>
<td>1725 - 1745</td>
<td>Measles/Rubella &amp; Microarray patch product development</td>
<td>Mark Papania (CDC)/Birgitte Giersing (WHO)</td>
</tr>
<tr>
<td>1745</td>
<td>Summary &amp; meeting close</td>
<td></td>
</tr>
<tr>
<td>1900 – 2100</td>
<td>Funders group meeting</td>
<td></td>
</tr>
</tbody>
</table>
2018 WHO Product Development for Vaccines Advisory Committee (PDVAC) Consultation
CHAIR: David Kaslow
26-27 June 2018 (28 June: closed session for committee members)
The Doha Room at the Starling Hotel, Geneva, Switzerland

<table>
<thead>
<tr>
<th>DAY3: Thursday, 28 June 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>0900 – 1600</td>
</tr>
<tr>
<td>Closed session: PDVAC committee only</td>
</tr>
<tr>
<td>To include GVAP reporting/recommendations</td>
</tr>
</tbody>
</table>